117 related articles for article (PubMed ID: 18027255)
1. Prostate cancer: the new evidence base for diagnosis and treatment.
Lamb DS; Slaney D; Smart R; Nacey JN; Russell G; Scott B; Johnson CA; Adams JD; Moran S; Delahunt B
Pathology; 2007 Dec; 39(6):537-44. PubMed ID: 18027255
[TBL] [Abstract][Full Text] [Related]
2. [Adenocarcinoma of the prostate].
Dvorácek J
Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
[TBL] [Abstract][Full Text] [Related]
3. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
4. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
5. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
6. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
9. Monograph series on aging-related diseases: X. Prostate cancer.
Ellison LF; Stokes J; Gibbons L; Lindsay J; Levy I; Morrison H
Chronic Dis Can; 1998; 19(1):1-18. PubMed ID: 9550730
[TBL] [Abstract][Full Text] [Related]
10. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
11. Screening men for prostate cancer and colorectal cancer: is practice evidence-based?
Chun FK; Suardi N; Perrotte P; Lebeau T; Guay JP; Benayoun S; Ramirez A; Bénard F; McCormack M; Valiquette L; Karakiewicz P
Can J Urol; 2007 Dec; 14(6):3727-33. PubMed ID: 18163923
[TBL] [Abstract][Full Text] [Related]
12. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
Lim LS; Sherin K;
Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
[TBL] [Abstract][Full Text] [Related]
13. [New aspects in prostate cancer therapy].
Dvorácek J
Cas Lek Cesk; 2007; 146(10):736-45. PubMed ID: 18020004
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study.
Pantanowitz L; Bohac G; Cooley TP; Aboulafia D; Dezube BJ
BJU Int; 2008 Jun; 101(12):1519-23. PubMed ID: 18384640
[TBL] [Abstract][Full Text] [Related]
15. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
Ito K
Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population.
Roemeling S; Roobol MJ; de Vries SH; Gosselaar C; van der Kwast TH; Schröder FH
J Urol; 2006 Apr; 175(4):1332-6. PubMed ID: 16515992
[TBL] [Abstract][Full Text] [Related]
18. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
Crawford ED; Abrahamsson PA
Eur Urol; 2008 Aug; 54(2):262-73. PubMed ID: 18556114
[TBL] [Abstract][Full Text] [Related]
19. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.
Nguyen PL; Chen MH; Catalona WJ; Alexander BM; Roehl KA; Loeb S; D'Amico AV
Cancer; 2008 Dec; 113(11):3146-52. PubMed ID: 18932254
[TBL] [Abstract][Full Text] [Related]
20. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
